Chaga Mushroom
SupplementThe large discrepancy results from a medically very weak evidence base (exclusively animal/in vitro data, no RCTs) [s6] versus a moderately positive community perception based on subjective experiential reports and traditional folk medicine [c1, c2, c3]. Typical of many adaptogens with a long folk medicine tradition.
Unlock full information
Dosages, side effects, studies and more — free after registration.
Register for freeRating Scales
TL;DR
Chaga contains antioxidant and immunomodulatory compounds like beta-glucans and betulinic acid, but their efficacy is supported only by animal and in-vitro studies — no human RCTs exist. The most concrete real-world risk is oxalate nephropathy: Chaga contains significant oxalic acid, and kidney damage from prolonged use is documented. Community reports are moderately positive but less enthusiastic than for Lion's Mane or Reishi. Its EU novel food status remains unresolved, making the quality and legality of many available products questionable.
Description
Parasitic fungus (Inonotus obliquus) with antioxidant, immunomodulatory, and anti-inflammatory properties; evidence to date primarily from animal and in vitro studies [s1, s2].
Chaga (Inonotus obliquus) is a parasitic fungus that grows preferentially on birch trees in Nordic and Siberian forests. It has been used traditionally for centuries in Siberia, Scandinavia, and Canada as a remedy, particularly for immune support and as a tea [s1, s2]. Chaga contains a broad spectrum of bioactive compounds: beta-glucans (polysaccharides), betulin and betulinic acid (derived from birch bark), inotodiol (a sterol), melanin, polyphenols, triterpenes, and minerals such as potassium, sodium, and manganese [s2, s3, s4]. The melanin content is responsible for the characteristic dark color and high antioxidant capacity [s3]. The scientific evidence available to date derives predominantly from in vitro and animal studies. Clinical human studies are very limited: a small 2016 human study showed increased natural killer cell activity after 8 weeks of Chaga consumption, but larger RCTs are lacking [s5]. Examine.com notes only one published human case series [s6]. The antitumor, hypoglycemic, and hypolipidemic effects demonstrated in animal and cell studies have not yet been confirmed in controlled human trials [s1, s7]. Safety concerns relate in particular to the high oxalic acid content, which can lead to oxalate nephropathy with excessive consumption, as documented by published case reports [s8, s9]. Interactions with anticoagulants, antidiabetics, and immunosuppressants have been described [s10, s11].
Legal Status (DE)
The legal status of Chaga in Germany and the EU is unresolved. Many medicinal mushrooms, potentially including Chaga, are classified as novel foods under the EU Novel Food Catalogue and may not be placed on the market as food supplements without authorization under Regulation (EU) 2015/2283 [s14, s15]. A history of traditional use in third countries may enable a simplified notification under Art. 14/15 of the Novel Food Regulation [s14]. However, products are frequently sold despite unresolved status. Consumers should verify the compliance of individual products [s15].
Mechanism of Action
The primary mechanisms of action of Chaga are attributed to the following compound groups [s3, s4]: 1. Beta-glucans (polysaccharides): Activate macrophages and regulate the TLR4/NF-κB signaling pathway, resulting in modulation of the immune response [s3]. Beta-glucans exhibit immunostimulatory, antitumor, hypoglycemic, hypolipidemic, and antiviral activities in vitro and in animal models [s4]. 2. Betulin and betulinic acid (derived from birch bark): Inhibit tumor cell proliferation and induce apoptosis in cell studies [s3, s7]. 3. Inotodiol (sterol): Inhibits cell migration and invasion and induces apoptosis via the p53-dependent pathway in cell cultures [s1]. The sterol demonstrated antitumor activity against cervical carcinoma cells in vitro [s11]. 4. Melanin and polyphenols: Act as potent antioxidants and neutralize reactive oxygen species (ROS). The ORAC value of Chaga is reported as 52,452 units [s12]. 5. Oxalic acid: As a byproduct of metabolic processes in the fungus, oxalate does not contribute to efficacy but poses a safety risk, as it can cause calcium oxalate deposits in the kidneys at high intake levels [s8, s9]. Overall, the postulated mechanisms are based on in vitro and animal data; direct transferability to humans has not been established [s6].
Dosing
Allgemeine Immununterstützung / Antioxidationsschutz
- Dose
- 500–1000 mg dry extract daily
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- mindestens 4–12 Wochen
- Timing
- Before or with meals
- With food
- empfohlen
Traditionelle Anwendung als Tee
- Dose
- 1–3 g chaga powder daily, brewed as tea
- Frequency
- 1–2× täglich
- Route
- oral
- Duration
- nach Bedarf
- Timing
- Morning or with meals
- With food
- optional
Therapeutische Anwendung (nicht standardisiert)
- Dose
- 1000–2000 mg extract daily; no consensus in the literature
- Frequency
- aufgeteilt auf 2 Dosen
- Route
- oral
- Duration
- begrenzt; keine Langzeitdaten beim Menschen
- Timing
- with meals
- With food
- empfohlen
No officially established upper limit exists (no RCT-based UL). Due to the high oxalic acid content, it is recommended not to permanently exceed daily doses of 3 g of raw material. In cases of pre-existing kidney disease or a tendency toward oxalate stones, Chaga should be avoided entirely [s8, s9, s10].
Extracts (e.g., 8:1 or 12:1 dual extract) are considerably more concentrated than raw material or powder [s13]. Bioavailability and optimal duration of use are not established due to the lack of human studies. No universal dosing consensus is available [s6].
Side Effects
| Side Effect | Frequency | Severity |
|---|---|---|
| Gastrointestinale Beschwerden (Übelkeit, Durchfall, Magenschmerzen) Occasionally described in anecdotal reports and review articles; no systematic frequency data from studies available [s2, s10]. | gelegentlich | leicht |
| Oxalatnephropathie (Nierenschäden durch Calciumoxalat-Ablagerungen) Documented in a case report: a 72-year-old patient developed renal insufficiency with oxalate deposits after 6 months of daily intake of 2 tsp Chaga powder [s8, s9]. | selten | schwer |
| Übermäßige Blutverdünnung / erhöhtes Blutungsrisiko Chaga contains platelet aggregation-inhibiting substances; additive effect possible when taken concomitantly with anticoagulants [s10, s11]. | theoretisch | moderat |
| Hypoglykämie (Unterzuckerung) Chaga demonstrated blood glucose-lowering properties in animal studies; additive effect possible with concurrent use of antidiabetic agents [s10, s11]. | theoretisch | moderat |
| Allergische Reaktionen As a fungal product, Chaga may trigger allergic reactions in individuals with fungal allergies; individual case reports described [s10]. | selten | moderat |
Contraindications
Chaga has a very high oxalic acid content. A documented case report of severe oxalate nephropathy following several months of consumption exists [s8, s9].
Chaga constituents may inhibit platelet aggregation and act additively with anticoagulants; increased bleeding risk [s10, s11].
Blood glucose-lowering effect in animal studies; additive hypoglycemic effect possible with antidiabetic agents [s10, s11].
Immunomodulatory beta-glucans may counteract the mechanism of action of immunosuppressants [s10, s11].
No human safety data available; contraindicated as a precautionary measure [s2, s6].
Interactions
Synergistic
Combination frequently used in mushroom complexes; additive immunomodulatory effect postulated but not clinically established [c3].
Chaga and ashwagandha are frequently used as an adaptogen combination. Both support the immune system and stress resilience in complementary ways.
Chaga and curcumin may act synergistically in mucosal inflammation. Both possess anti-inflammatory properties that are purported to complement each other.
Caution
Additive bleeding risk due to platelet aggregation-inhibiting activity of Chaga constituents [s10, s11].
Additive blood glucose-lowering effect demonstrated in animal studies; hypoglycemia risk in humans possible [s10, s11].
Immunostimulatory beta-glucans can antagonize immunosuppressive therapies [s10, s11].
Both substances can lower blood glucose. Concurrent use carries an increased risk of hypoglycemia, particularly in individuals with diabetes.
Both substances influence blood glucose and insulin metabolism. When combined, blood glucose should be monitored closely.
Studies
Tier B — Moderate Evidence
Outcome: Increased natural killer cell activity and altered cytokine production following Chaga consumption
Effect Size: Positive signal; no quantitative effect measures reported; no control group
Outcome: Summary of therapeutic properties of I. obliquus incl. antitumoral, antioxidant, immunomodulatory
Effect Size: Qualitative; predominantly animal and in vitro data
Outcome: Overview of medical and nutraceutical significance of I. obliquus
Effect Size: Qualitative; predominantly in vitro and animal data
Tier C — Low Evidence
Outcome: Biological activities of I. obliquus polysaccharides incl. immunomodulation, antitumor, antioxidant
Effect Size: Preclinical; no human data
Outcome: Constituents, mechanisms, and health functions of I. obliquus
Effect Size: Summary of preclinical data
Outcome: Antitumor activity of Chaga subfractions in cancer cell lines and mouse model (Sarcoma-180)
Effect Size: Significant tumor reduction in mouse model; no human data
Outcome: Oxalate nephropathy following chronic Chaga consumption
Effect Size: Severe renal insufficiency, dialysis dependency
Community Evidence
Top reported benefits
- Improved digestion and fewer gastrointestinal issues
- General well-being and energy
- Reduced inflammation symptoms (joints, headaches)
- Better concentration (as part of mushroom complexes)
- Immune enhancement based on subjective perception
Top reported issues
- Lack of noticeable effect in many users
- Occasional gastrointestinal issues with powder form
- Unclear legal status and quality variations between products
- Concerns about renal damage with long-term use
The user community is smaller than for Lion's Mane or Reishi. Safety concerns regarding oxalic acid are increasingly discussed in forums, particularly following reports of kidney damage [c2]. Quality differences between products (raw powder vs. extract) are perceived as a problem. Note: The number of analyzed threads is fewer than 30 due to limited Chaga-specific community activity; all available relevant posts were taken into account.
Scientific Sources
- Therapeutic properties of Inonotus obliquus (Chaga mushroom): A review
Géry A, Dubreule C, André V, et al. (2023). Mycology: An International Journal on Fungal BiologyBPMID:38813471DOI - Chaga Mushroom Side Effects: What the Research Actually Shows (2026)
Advanced MycoTech Editorial Team (2026). Advanced MycoTech BlogCLink - Chaga Mushroom – Integrative Medicine Summary
Memorial Sloan Kettering Cancer Center Editorial Team (2023). MSKCC Integrative MedicineBLink - Chaga Pilz Wirkung und Risiken + Anwendung (ORAC-Wert Chaga)
Chaga-pilz.com Redaktion (2023). chaga-pilz.comCLink - Chaga-Extrakt: Wirkung, Dosierung & Sicherheit
NahrungsHub Redaktion (2024). nahrung-ergaenzungsmittel.deCLink - Novel Food – Neuartige Lebensmittel (BVL)
Bundesamt für Verbraucherschutz und Lebensmittelsicherheit (BVL) (2023). BVL – Bundesamt für Verbraucherschutz und LebensmittelsicherheitALink - Vitalpilze für die Krebstherapie? (Verbraucherzentrale)
Verbraucherzentrale Deutschland (2022). Verbraucherzentrale.deALink - A brief overview of the medicinal and nutraceutical importance of Inonotus obliquus (chaga) mushrooms
Wagle A, Seong SH, Choi JS, et al. (2024). HeliyonBDOI - Natural Products and Health Care Functions of Inonotus obliquus
Liu Y, Wang J, Wang W, et al. (2025). Current Issues in Molecular Biology (MDPI)BDOI - Inonotus obliquus Polysaccharides: Preparation, Structural Characteristics, Structure-Activity Relationships, Biological Activities and Applications
Wang X, Li H, Zhang Y, et al. (2025). PubMed (ahead of print)BPMID:41978174 - Chaga Mushroom: Evidence Review for Immunity & Antioxidant Support (citing 2016 human pilot study on NK cell activity)
Kasivit Editorial Team (2024). Kasivit Wellness BlogCLink - Chaga – Supplement Overview (Examine.com)
Examine.com Editorial Team (2024). Examine.comDLink - Anticancer activity of subfractions containing pure compounds of Chaga mushroom (Inonotus obliquus) extract in human cancer cells and in Balbc/c mice bearing Sarcoma-180 cells
Zheng W, Miao K, Liu Y, et al. (2010). PMC (Journal of Ethnopharmacology)CLink - Chaga mushroom-induced oxalate nephropathy
Kikuchi Y, Seta K, Ogawa Y, et al. (2014). Clinical NephrologyCPMID:23149251 - Chaga mushroom-induced oxalate nephropathy that clinically resembled metastatic disease
Spector J, Saperia J, Golbus J, et al. (2022). PMC / Case Reports in NephrologyCLink
Community Sources
Storage
Unopened
Store in a cool, dry, light-protected location at room temperature.
Opened
Keep tightly sealed; avoid moisture, as the product is hygroscopic.
Notes
Chaga extracts and powders are light-sensitive due to their melanin content. Optimal storage below 25 °C, protected from direct sunlight.